Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 20,994 matching trials from the live ClinicalTrials.gov search.
Conditions
Guillain-Barré Syndrome, Miller Fisher Syndrome
Interventions
Not listed
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Alemtuzumab, Interferon beta-1a
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
36
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more
Conditions
Muckle Wells Syndrome
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
4 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Madison, Wisconsin
Completed Not applicable Interventional Results available

Telehealth Pain Self-Management for Employed Adults

NCT04248725
Conditions
Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries, Amputation
Interventions
E-TIPS
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Miami Shores, Florida • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Tucson, Arizona • Concord, California • Encino, California + 49 more
Conditions
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions
brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
32
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
Conditions
Rheumatoid Arthritis
Interventions
New formulation adalimumab
Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Mesa, Arizona • Hemet, California • Wichita, Kansas + 3 more
Active, not recruiting Phase 2 Interventional

MMRC Horizon One: RRMM (MMRC-099)

NCT06171685
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Teclistamab Monotherapy, Teclistamab
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity Trial of IHV01

NCT02756208
Conditions
HIV Infection
Interventions
300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine, Placebo
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

NCT00925925
Conditions
Low Birth Weight, Small for Gestational Age, Immunodeficiency
Interventions
Cord blood collection for analysis
Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Hours
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Pembrolizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Chronic Pain Syndrome
Interventions
MBSR treatment
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Lymphoma
Interventions
bexarotene, methoxsalen, UV light therapy
Drug · Procedure
Lead sponsor
Millennix
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more
Conditions
Multiple Myeloma
Interventions
Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Conditions
Eosinophilic Esophagitis
Interventions
Cendakimab, CYP substrates
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
Conditions
Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
Interventions
Chart review
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
6 Months to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Cincinnati, Ohio + 1 more
Conditions
Milk Allergy
Interventions
Experimental Extensively Hydrolyzed Formula, Active Comparator Formula
Other
Lead sponsor
Perrigo Nutritionals
Industry
Eligibility
Up to 13 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 15 more
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Withdrawn No phase listed Observational

Clinical Performance of BioCLIA Ro60

NCT03204448
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome
Interventions
BioCLIA Ro60
Device
Lead sponsor
HOB Biotech Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Irvine, California
Conditions
Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions
Stem Cell Transplantation, Busulfan, Melphalan
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Enrolling by invitation No phase listed Observational

Serum Auto-Antibodies in Neurological Diseases

NCT00704626
Conditions
Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
Interventions
Blood Draw, Cheek swab
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2031
U.S. locations
1
States / cities
Sacramento, California
Conditions
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
Interventions
Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland